CAH
Cardinal Health·NYSE
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 2
Consensus Rating "Buy"
High Cash/net Profit Ratio
EPS Below Expectations
Consecutive Gross Margin Decline
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CAH
Cardinal Health, Inc.
A distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for health care facilities
Healthcare Providers and Services
--
09/07/1994
New York Stock Exchange
57,700
06-30
Common stock
7000 Cardinal Place, Dublin, Ohio 43017
--
Cardinal Health, Inc., an Ohio company founded in 1979, is a globally integrated healthcare services and products company that provides customized solutions for hospitals, healthcare systems, pharmacies, outpatient surgery centers, clinical laboratories, physician offices and home patients. The company provides pharmaceutical and medical products and cost-effective solutions to improve supply chain efficiency. The company connects patients, providers, payers, pharmacists and manufacturers to achieve comprehensive care coordination and better patient management. The company manages its business and reports its financial results, divided into two parts: pharmaceutical and medical.
Earnings Call
Q3/2025
Estimate EPS2.15
Actual EPS2.35
Estimate Revenue55.31B
Actual Revenue54.90B
Cardinal Health's Q3 2025: Dissecting Key Contradictions in Specialty Drugs, Generics, and Margins
May 02,2025 07:28
Earnings Decrypt
Earnings Decrypt
Q4/2025
Estimate EPS2.03
Actual EPS2.08
Estimate Revenue60.92B
Actual Revenue60.16B
Contradictions Unveiled: Analyzing Cardinal Health's Q4 2025 Earnings Call Insights on Tariffs and Pharma Growth
Aug 12,2025 11:28
Earnings Decrypt
Earnings Decrypt
Q1/2026
Estimate EPS2.17
Actual EPS2.55
Estimate Revenue59.27B
Actual Revenue64.00B
Cardinal Health's Q1 2026 Earnings Call: Contradictions in Specialty Growth, Tariff Impacts, and Biosimilars Strategy
Oct 30,2025 01:16
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
CAH has released its 2026 Q1 earnings. EPS was reported at 2.55, versus the expected 2.17, beating expectations. The chart below visualizes how CAH has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
CAH has released its 2026 Q1 earnings report, with revenue of 64.01B, reflecting a YoY change of 22.44%, and net profit of 454.00M, showing a YoY change of 8.87%. The Sankey diagram below clearly presents CAH's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
